9 Meters Biopharma, Inc.

NasdaqCM:NMTR Stock Report

Market Cap: US$2.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Valuation

Is NMTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NMTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NMTR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NMTR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMTR?

Key metric: As NMTR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NMTR. This is calculated by dividing NMTR's market cap by their current book value.
What is NMTR's PB Ratio?
PB Ratio-0.4x
Book-US$6.30m
Market CapUS$2.82m

Price to Book Ratio vs Peers

How does NMTR's PB Ratio compare to its peers?

The above table shows the PB ratio for NMTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.5x
SNES SenesTech
0.7x15.2%US$2.5m
AKAN Akanda
0.5xn/aUS$2.1m
INM InMed Pharmaceuticals
0.4xn/aUS$3.2m
CPHI China Pharma Holdings
0.6xn/aUS$3.9m
NMTR 9 Meters Biopharma
n/a41.4%US$2.8m

Price-To-Book vs Peers: NMTR is good value based on its Price-To-Book Ratio (-0.4x) compared to the peer average (2167.7x).

Price to Book Ratio vs Industry

How does NMTR's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.86m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.93m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.45m
NMTR is unprofitableIndustry Avg. 1.7xNo. of Companies29PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NMTR is good value based on its Price-To-Book Ratio (-0.4x) compared to the US Pharmaceuticals industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is NMTR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMTR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NMTR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NMTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Nov ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Oct ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Sep ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Aug ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Jul ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Jun ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
May ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Apr ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Mar ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Feb ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Jan ’25US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Dec ’24US$0.000001
US$9.58
+958,332,900.0%
82.8%US$20.00US$0.75n/a3
Nov ’24US$0.0001
US$9.58
+9,583,230.0%
82.8%US$20.00US$0.75US$0.0000013
Oct ’24US$0.012
US$9.58
+79,761.1%
82.8%US$20.00US$0.75US$0.0000013
Sep ’24US$0.014
US$9.58
+68,352.4%
82.8%US$20.00US$0.75US$0.0000013
Aug ’24US$0.023
US$9.58
+42,117.3%
82.8%US$20.00US$0.75US$0.0000013
Jul ’24US$0.67
US$9.58
+1,326.1%
82.8%US$20.00US$0.75US$0.0000013
Jun ’24US$0.71
US$9.58
+1,255.9%
82.8%US$20.00US$0.75US$0.0000013
May ’24US$0.75
US$17.93
+2,290.0%
79.8%US$40.00US$1.70US$0.0000014
Apr ’24US$1.39
US$17.93
+1,189.6%
79.8%US$40.00US$1.70US$0.0000014
Mar ’24US$1.67
US$33.12
+1,883.0%
69.7%US$74.00US$2.70US$0.0000016
Feb ’24US$2.16
US$39.20
+1,714.8%
52.1%US$74.00US$10.00US$0.0000015
Jan ’24US$1.26
US$39.20
+3,011.1%
52.1%US$74.00US$10.00US$0.0000015
Dec ’23US$1.71
US$39.20
+2,192.4%
52.1%US$74.00US$10.00US$0.0000015
Nov ’23US$2.53
US$66.80
+2,540.3%
29.7%US$100.00US$40.00US$0.00015

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.79

7D

5.4%

1Y

19.1%